[Anti-angiogenic drugs and hypertension: from multidisciplinary collaboration to greater care].
anti-angiogenic drugs
hypertension
kidney injury
multidisciplinary team
ovarian cancer
proteinuria
Journal
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
ISSN: 1724-5990
Titre abrégé: G Ital Nefrol
Pays: Italy
ID NLM: 9426434
Informations de publication
Date de publication:
21 Dec 2022
21 Dec 2022
Historique:
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
Anti-angiogenic drugs are widely used in cancer therapy. Their main targets of action are the vascular endothelial growth factor (VEGF) and its receptors (VEGF-R). Anti-angiogenic drugs are used to reduce the growth of the tumor and its metastases by acting on the phenomenon of tumor neo-angiogenesis. However, they are known for their side effects such as hypertension, acute kidney injury (AKI), and congestive heart failure.
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Vascular Endothelial Growth Factor A
0
Types de publication
Case Reports
English Abstract
Langues
ita
Sous-ensembles de citation
IM
Informations de copyright
Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.